+ Watch OPK
on My Watchlist
Frost is in the business of making money! His track record speaks for itself.
downward movement more likely than upward
OPKO Health Inc. has a big year ahead of it. The 4Kscore™ Prostate Cancer Test is a revolutionary development in the medical field. It allows a health professional to create a detailed assessment rating of a male patient's risk for developing prostate cancer. Not only is this less invasive than traditional methods, but overall it will create a large cost savings by decreasing the amount of expensive biopsies conducted. This tool has the potential to create a better system of patient assessment, help health professionals find signs of prostate cancer in the earliest stages, decrease fatalities, increase patient compliance because of its non-invasive nature, and decrease the cost of health care. OPKO Health Inc. has a bright future ahead of it. I am excited to see what other innovative technologies they can bring the forefront of of the health care system not only in the U.S but also throughout the world.
Pipeline emerges in the next couple of years. Beginning in 2014.
A vote of confidence in Dr. Frost.
Frost run company
tight progressive and innovative leadership..with major ownership investment and in the company
I think that OPK has alot of potential to the upside. It is trying to establish a foothold in a great industry and has made some aquisitions that will help in the near ftrure. I would buy this and hold to see if other investors have the same thoughts.
OPKO health is a pure play on Dr. Philip Frost and his ability to create companies in this sector and then sell them for large shareholder gains. Dr. Frost also continues to be a buyer in the M+A world of little known company's that fit into what he is trying to accomplish. My gut tells me to never bet against self made men like Dr. Philip Frost and I'm going to ride his coat tails this time. He obviously believes in what he is doing as he has continually purchases shares in this company, over the counter, for the last 2 years.
I see a lot of speculation here about a buyout, but let's get back to reality. It doesn't seem likely that any company will pay over $2 billion for just $170 million in net assets and less than $40 million in annual revenue. Opko goes from a measly $5-$6 million in quarterly revenue to $11 and all of a sudden its the best company ever? Look closer and you'll see that a near doubling in revenue resulted in an even larger loss than last year!
pipeline of novel in house testing for doctors
It will snapped up by one of the big pharmas
Insiders buying on insider insight on insider information. Three good reasons to buy now.
CEO is buying a ton of shares, so I'm initiating this to see what happens.
Nice technicals, and management!
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions